Walleye Trading
OCUL icon

Walleye Trading’s Ocular Therapeutix OCUL Stock Holding History

Walleye Trading’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,165
Closed -$173K – 4525
2025
Q4 		$221K Buy
+18,165
New +$221K ﹤0.01% 3337
2023
Q3 		– Sell
-45,115
Closed -$233K – 5234
2023
Q2 		$233K Sell
45,115
-4,601
-9% -$27.4K ﹤0.01% 3332
2023
Q1 		$262K Buy
+49,716
New +$236K ﹤0.01% 3317
2022
Q1 		– Sell
-3,880
Closed -$27K – 5732
2021
Q4 		$27K Buy
+3,880
New +$30.1K ﹤0.01% 4845
2021
Q3 		– Sell
-5,657
Closed -$80K – 5555
2021
Q2 		$80K Buy
+5,657
New +$86K ﹤0.01% 4464
2020
Q3 		– Sell
-17,900
Closed -$149K – 4469
2020
Q2 		$149K Buy
+17,900
New +$119K ﹤0.01% 3277
2018
Q4 		– Sell
-1,058
Closed -$7K – 5104
2018
Q3 		$7K Buy
+1,058
New +$6.64K ﹤0.01% 5064
2017
Q1 		– Sell
-200
Closed -$2K – 5029
2016
Q4 		$2K Buy
+200
New +$1.55K ﹤0.01% 4565

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Walleye Trading's OCUL Position: Q1 2026 in Review

Walleye Trading sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 18,165 shares — an estimated $173K sold.

Walleye Trading first reported a position in OCUL in Q4 2016 and held it in 8 quarters. The position peaked at $262K in Q1 2023. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Walleye Trading reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 18,165 Ocular Therapeutix shares in Q1 2026, an estimated $173K.
  • Walleye Trading first reported a position in Ocular Therapeutix in Q4 2016 and held it in 8 quarters.
  • Walleye Trading's Ocular Therapeutix position peaked at $262K in Q1 2023.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.